Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
About this item
Full title
Author / Creator
Peters, Solange , Camidge, D. Ross , Shaw, Alice T , Gadgeel, Shirish , Ahn, Jin S , Kim, Dong-Wan , Ou, Sai-Hong I , Pérol, Maurice , Dziadziuszko, Rafal , Rosell, Rafael , Zeaiter, Ali , Mitry, Emmanuel , Golding, Sophie , Balas, Bogdana , Noe, Johannes , Morcos, Peter N , Mok, Tony and ALEX Trial Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with
ALK
-positive non–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse.
Alternative Titles
Full title
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1934032205
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1934032205
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1704795
